Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Medmira ( (TSE:MIR) ) is now available.
MedMira Inc. has received Investigational Testing Authorizations from Health Canada to begin clinical trials for self-testing and non-professional use of its Multiplo® TP/HIV rapid test. This move is significant amid rising syphilis and HIV cases in Canada, especially in the Prairie regions, as it aims to provide accessible testing options for individuals who face barriers to healthcare. The trials, supported by the Canadian Institutes of Health Research, will be conducted by REACH Nexus at the MAP Centre for Urban Health Solutions. The tests are designed to offer quick, reliable results from a single finger-prick blood sample, potentially allowing users to confirm positive results through lab tests and access treatment promptly.
More about Medmira
MedMira Inc. is a healthcare company that specializes in the development and commercialization of rapid diagnostic tests. Its primary products include the Multiplo® TP/HIV rapid test, which focuses on providing solutions for detecting syphilis and HIV. The company aims to expand access to testing, particularly in underserved markets affected by rising infection rates.
YTD Price Performance: 13.64%
Average Trading Volume: 94,595
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$94.79M
For a thorough assessment of MIR stock, go to TipRanks’ Stock Analysis page.